{"filing":{"accession_number":"0000879169-26-000046","cik":"0000879169","ticker":"INCY","company_name":"INCYTE CORP","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"incy-20260622.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000046/incy-20260622.htm"},"events":[{"id":12559,"run_id":11138,"accession_number":"0000879169-26-000046","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"Incyte announced settlement of litigation with CMS regarding Medicaid rebate rules applied to Opzelura (ruxolitinib) cream. The settlement involves withdrawal of the company's lawsuit and a one-time non-cash benefit of approximately $246 million from reversal of previously established accrual balances, with material improvement to Opzelura's gross-to-net margins going forward. This is a material litigation settlement with significant financial consequences.","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9440,"accession_number":"0000879169-26-000046","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Incyte announced settlement of litigation with CMS regarding Medicaid rebate rules applied to Opzelura (ruxolitinib) cream. The settlement involves withdrawal of the company's lawsuit and a one-time non-cash benefit of approximately $246 million from reversal of previously established accrual balances, with material improvement to Opzelura's gross-to-net margins going forward. This is a material litigation settlement with significant financial consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:01:25.655629+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9440,"accession_number":"0000879169-26-000046","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Incyte announced settlement of litigation with CMS regarding Medicaid rebate rules applied to Opzelura (ruxolitinib) cream. The settlement involves withdrawal of the company's lawsuit and a one-time non-cash benefit of approximately $246 million from reversal of previously established accrual balances, with material improvement to Opzelura's gross-to-net margins going forward. This is a material litigation settlement with significant financial consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:01:25.655629+00:00","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-06-22"}]}